Lupin gets warning letter from USFDA for Somerset facility

The United States Food and Drug Administration (USFDA) had inspected the company's Somerset, New Jersey, facility from September 10, 2020, to November 5, 2020, Lupin said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3wlc6b3
via IFTTT